N-acetylcysteine in Bulimia Nervosa

Phase 2

Terminated

• Conditions: NAC
• Interventions: Drug: N-acetylcysteine NAC

• Registration Number: NCT01131572
• Lead Sponsor: Lindner Center of HOPE

Brief Summary

This study tests NAC in the treatment of Bulimia Nervosa.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-02
• Study First Submitted: 2010-05-24
• Study First Submitted QC: 2010-05-26
• Study First Posted: 2010-05-27
• Primary Completion: 2012-03
• Study Completion: 2012-03
• Status Verified: 2013-05
• Last Update Submitted: 2013-05-08
• Last Update Posted: 2013-05-10

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

• Bulimia Nervosa
• 18-65 years of age

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
N-acetylcysteine	N-acetylcysteine NAC	open label treatment. Each subject receives N-acetylcysteine.

Primary Outcome Measures

Name	Time	Method
Binge-purge episodes	per week	The primary outcome measure will be the weekly frequency of binge-purge episodes. A binge-purge eating episode will be defined using DSM-IV-TR criteria, and accessed via clinical interview and review of subject take-home diaries at each study visit.

Trial Locations

Locations (1)

Lindner Center of HOPE; 🇺🇸 Mason, Ohio, United States